Dianthus Therapeutics, Inc. (DNTH) is advancing its potential best-in-class complement inhibitor drug DNTH103 for a wide variety of autoimmune disorders. In particular, it is looking at advancing the ...

Study of lead program will provide proof-of-concept to enable further clinical development in severe autoimmune diseases; full cohort data available in 2H'23 DNTH103 is a next-generation monoclonal ...

The complement pathway is a regulated cascade of proteins that supports or complements (hence the name) the activity of antibodies and phagocytes in clearing infections. The pathway comprises three ...

Dianthus Therapeutics' DNTH103, a selective C1s inhibitor, is in phase 2 trials for gMG, CIDP, and MMN, offering a differentiated, convenient dosing profile. DNTH103's selective targeting minimizes ...

Phase I Clinical Trial in healthy subjects shows that NM3086 was safe and well tolerated at all doses (0.1 to 20 mg/kg) in six cohorts. Total AP inhibition was achieved through all cohorts and the ...

Immunoglobulin A (IgA) nephropathy results from the accumulation of IgA-containing immune complexes (IgA-ICs) and aberrant ...

A study shows elevated CFHR1 promotes immune complex buildup in kidneys, offering insights into disease mechanisms, enabling ...